article thumbnail

Icentia Receives U.S. Food and Drug Administration (FDA) Clearance for CardioSTAT®

Legacy MEDSearch

Food and Drug Administration (FDA) Clearance for CardioSTAT® Press Release by: Icentia Legacy MedSearch has more than 35 years of combined experience recruiting in the medical device industry. Food and Drug Administration (FDA) Clearance for CardioSTAT® appeared first on Legacy MedSearch | Medical Device Recruiters.

article thumbnail

Pharma Injecting Life into Digital Health Amidst Funding Downturn

MedCity News

Investors in 2022 appeared confident that the continued transformation of drug research and development protocols and the overall life sciences industry will not only include digital health solutions, but will even depend on them for data collection, analysis, patient engagement, and even their therapeutic properties.

Pharma 306
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Enable Injections Receives First U.S. Food and Drug Administration (FDA) Approval

Legacy MEDSearch

Food and Drug Administration (FDA) has approved the EMPAVELI Injector (enFuse ® ) for the subcutaneous delivery of EMPAVELI ® (pegcetacoplan), which is commercialized in the United States by Apellis Pharmaceuticals, Inc. “Enable’s purpose is to redefine drug delivery for the benefit of patients. .

article thumbnail

PolarisAR Receives Clearance from the U.S. Food and Drug Administration for Stellar Knee

Legacy MEDSearch

Food and Drug Administration (FDA). FOOD AND DRUG ADMINISTRATION FOR STELLAR KNEE Press Release by: POLARISAR Legacy MedSearch has more than 35 years of combined experience recruiting in the medical device industry. See Full Press Release at the Source: POLARIS AR RECEIVES CLEARANCE FROM THE U.S.

article thumbnail

AI to revolutionise drug development by 2026

European Pharmaceutical Review

Initial data from the CPHI Annual Report 2023, which provides insight from 250 global pharmaceutical companies, reveals that AI (artificial intelligence) is expected to transform every area of the industry, from drug discovery through to drug development , within the next 24-months. Attending CPHI Barcelona 2023?

article thumbnail

First AI-generated small molecule drug enters Phase II trial

European Pharmaceutical Review

The world’s first AI-generated anti-fibrotic small molecule inhibitor drug has been administered to the first human patients. Phase II clinical trials in the US and China are now underway for INS018_055, Insilico Medicine’s potentially first-in-class oral drug candidate. Patients will be divided into four parallel cohorts.

article thumbnail

What Pear Therapeutics’ Bankruptcy Has Left the DTX Industry to Ponder

MedCity News

Combined, DTx and DCTs improve patient recruitment, retention, and access, allowing researchers to pull from underserved communities, including rural populations. Orexo is a Swedish company that makes good money selling a drug called Zubsolv for opioid use disorder in the United States. The result was more diverse and inclusive data.